Evoke Free Cash Flow Per Share vs Days Payables Outstanding Analysis

EVOK Stock

USD 4.17 0.03 0.71%

Evoke Pharma financial indicator trend analysis is much more than just examining Evoke Pharma latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Evoke Pharma is a good investment. Please check the relationship between Evoke Pharma Free Cash Flow Per Share and its Days Payables Outstanding accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evoke Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.

Free Cash Flow Per Share vs Days Payables Outstanding

Free Cash Flow Per Share vs Days Payables Outstanding Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Evoke Pharma Free Cash Flow Per Share account and Days Payables Outstanding. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Evoke Pharma's Free Cash Flow Per Share and Days Payables Outstanding is -0.41. Overlapping area represents the amount of variation of Free Cash Flow Per Share that can explain the historical movement of Days Payables Outstanding in the same time period over historical financial statements of Evoke Pharma, assuming nothing else is changed. The correlation between historical values of Evoke Pharma's Free Cash Flow Per Share and Days Payables Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Per Share of Evoke Pharma are associated (or correlated) with its Days Payables Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Days Payables Outstanding has no effect on the direction of Free Cash Flow Per Share i.e., Evoke Pharma's Free Cash Flow Per Share and Days Payables Outstanding go up and down completely randomly.

Correlation Coefficient

-0.41

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Days Payables Outstanding

Most indicators from Evoke Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Evoke Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evoke Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.Selling General Administrative is expected to rise to about 13.3 M this year, although the value of Issuance Of Capital Stock will most likely fall to 0.00.

Evoke Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Long Term Debt	Other Liab	Net Tangible Assets	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Retained Earnings Total Equity	Long Term Debt Total
Total Assets		0.08	0.12	0.9	-0.81	-0.1	0.35	0.98	0.98	0.15	-0.05	-0.65	0.15	0.29	-0.62	1.0	0.11	0.41	0.16	0.24	-0.14	-0.2	-0.21	-0.16	-0.07	0.14
Other Current Liab	0.08		0.66	0.09	0.17	-0.49	0.55	0.0	0.0	0.52	0.07	-0.36	0.5	0.5	-0.12	0.08	0.33	0.4	0.44	0.03	-0.64	-0.32	-0.34	-0.41	-0.52	0.53
Total Current Liabilities	0.12	0.66		0.02	0.36	-0.65	0.47	-0.06	-0.06	0.72	-0.19	-0.24	0.58	0.58	-0.11	0.11	-0.1	0.58	0.46	-0.08	-0.45	-0.09	-0.06	-0.27	-0.58	0.42
Total Stockholder Equity	0.9	0.09	0.02		-0.81	-0.22	0.55	0.89	0.89	0.25	0.35	-0.88	0.17	0.43	-0.88	0.9	0.33	0.22	0.27	0.34	-0.36	-0.49	-0.48	-0.47	-0.23	0.4
Net Debt	-0.81	0.17	0.36	-0.81		-0.31	-0.15	-0.9	-0.9	0.27	-0.21	0.52	0.33	0.09	0.55	-0.82	-0.15	0.14	0.24	-0.23	-0.14	0.07	0.05	-0.01	-0.29	0.12
Retained Earnings	-0.1	-0.49	-0.65	-0.22	-0.31		-0.52	0.05	0.05	-0.97	-0.15	0.5	-0.81	-0.94	0.41	-0.09	-0.38	-0.53	-0.7	0.05	0.81	0.56	0.63	0.62	0.98	-0.83
Accounts Payable	0.35	0.55	0.47	0.55	-0.15	-0.52		0.27	0.27	0.48	0.43	-0.75	0.37	0.64	-0.69	0.35	0.21	0.28	0.38	0.61	-0.76	-0.76	-0.65	-0.83	-0.51	0.79
Cash	0.98	0.0	-0.06	0.89	-0.9	0.05	0.27		1.0	0.0	-0.01	-0.61	0.01	0.15	-0.59	0.98	0.14	0.27	0.04	0.25	-0.05	-0.16	-0.17	-0.1	0.06	0.04
Cash And Short Term Investments	0.98	0.0	-0.06	0.89	-0.9	0.05	0.27	1.0		0.0	-0.01	-0.61	0.01	0.15	-0.59	0.98	0.14	0.27	0.04	0.25	-0.05	-0.16	-0.17	-0.1	0.06	0.04
Common Stock Total Equity	0.15	0.52	0.72	0.25	0.27	-0.97	0.48	0.0	0.0		0.16	-0.53	0.78	0.91	-0.43	0.15	0.4	0.51	0.68	-0.12	-0.77	-0.49	-0.57	-0.58	-0.96	0.78
Common Stock Shares Outstanding	-0.05	0.07	-0.19	0.35	-0.21	-0.15	0.43	-0.01	-0.01	0.16		-0.6	-0.12	0.21	-0.66	-0.05	0.45	-0.55	0.1	0.21	-0.4	-0.53	-0.51	-0.62	-0.24	0.46
Non Current Liabilities Total	-0.65	-0.36	-0.24	-0.88	0.52	0.5	-0.75	-0.61	-0.61	-0.53	-0.6		-0.33	-0.64	0.96	-0.65	-0.51	-0.17	-0.46	-0.32	0.69	0.72	0.7	0.76	0.54	-0.7
Other Current Assets	0.15	0.5	0.58	0.17	0.33	-0.81	0.37	0.01	0.01	0.78	-0.12	-0.33		0.82	-0.21	0.14	0.28	0.78	0.81	-0.12	-0.64	-0.37	-0.47	-0.39	-0.78	0.62
Other Stockholder Equity	0.29	0.5	0.58	0.43	0.09	-0.94	0.64	0.15	0.15	0.91	0.21	-0.64	0.82		-0.55	0.28	0.41	0.56	0.73	0.03	-0.8	-0.61	-0.67	-0.65	-0.92	0.87
Total Liab	-0.62	-0.12	-0.11	-0.88	0.55	0.41	-0.69	-0.59	-0.59	-0.43	-0.66	0.96	-0.21	-0.55		-0.62	-0.42	-0.05	-0.37	-0.36	0.57	0.7	0.66	0.74	0.44	-0.63
Total Current Assets	1.0	0.08	0.11	0.9	-0.82	-0.09	0.35	0.98	0.98	0.15	-0.05	-0.65	0.14	0.28	-0.62		0.12	0.41	0.16	0.25	-0.14	-0.21	-0.22	-0.17	-0.07	0.14
Common Stock	0.11	0.33	-0.1	0.33	-0.15	-0.38	0.21	0.14	0.14	0.4	0.45	-0.51	0.28	0.41	-0.42	0.12		-0.02	0.32	-0.07	-0.56	-0.56	-0.58	-0.46	-0.5	0.5
Short Long Term Debt Total	0.41	0.4	0.58	0.22	0.14	-0.53	0.28	0.27	0.27	0.51	-0.55	-0.17	0.78	0.56	-0.05	0.41	-0.02		0.67	0.04	-0.37	-0.18	-0.24	-0.16	-0.45	0.34
Long Term Debt	0.16	0.44	0.46	0.27	0.24	-0.7	0.38	0.04	0.04	0.68	0.1	-0.46	0.81	0.73	-0.37	0.16	0.32	0.67		-0.18	-0.58	-0.43	-0.52	-0.47	-0.68	0.62
Other Liab	0.24	0.03	-0.08	0.34	-0.23	0.05	0.61	0.25	0.25	-0.12	0.21	-0.32	-0.12	0.03	-0.36	0.25	-0.07	0.04	-0.18		-0.37	-0.61	-0.48	-0.58	0.05	0.37
Net Tangible Assets	-0.14	-0.64	-0.45	-0.36	-0.14	0.81	-0.76	-0.05	-0.05	-0.77	-0.4	0.69	-0.64	-0.8	0.57	-0.14	-0.56	-0.37	-0.58	-0.37		0.88	0.89	0.9	0.86	-0.95
Non Current Assets Total	-0.2	-0.32	-0.09	-0.49	0.07	0.56	-0.76	-0.16	-0.16	-0.49	-0.53	0.72	-0.37	-0.61	0.7	-0.21	-0.56	-0.18	-0.43	-0.61	0.88		0.95	0.95	0.62	-0.88
Non Currrent Assets Other	-0.21	-0.34	-0.06	-0.48	0.05	0.63	-0.65	-0.17	-0.17	-0.57	-0.51	0.7	-0.47	-0.67	0.66	-0.22	-0.58	-0.24	-0.52	-0.48	0.89	0.95		0.91	0.7	-0.89
Other Assets	-0.16	-0.41	-0.27	-0.47	-0.01	0.62	-0.83	-0.1	-0.1	-0.58	-0.62	0.76	-0.39	-0.65	0.74	-0.17	-0.46	-0.16	-0.47	-0.58	0.9	0.95	0.91		0.67	-0.91
Retained Earnings Total Equity	-0.07	-0.52	-0.58	-0.23	-0.29	0.98	-0.51	0.06	0.06	-0.96	-0.24	0.54	-0.78	-0.92	0.44	-0.07	-0.5	-0.45	-0.68	0.05	0.86	0.62	0.7	0.67		-0.85
Long Term Debt Total	0.14	0.53	0.42	0.4	0.12	-0.83	0.79	0.04	0.04	0.78	0.46	-0.7	0.62	0.87	-0.63	0.14	0.5	0.34	0.62	0.37	-0.95	-0.88	-0.89	-0.91	-0.85

Click cells to compare fundamentals

Evoke Pharma Account Relationship Matchups

Evoke Pharma fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	9.4M	10.6M	11.9M	7.1M	8.1M	10.1M
Other Current Liab	6.0M	506.9K	528.1K	2.9M	3.4M	1.9M
Total Current Liabilities	7.5M	1.4M	1.7M	9.6M	11.1M	11.7M
Total Stockholder Equity	(3.2M)	3.6M	4.1M	(2.6M)	(3.0M)	(2.8M)
Net Debt	(2.8M)	(4.1M)	(4.7M)	260.6K	299.7K	314.6K
Retained Earnings	(98.9M)	(107.4M)	(115.6M)	(123.4M)	(111.1M)	(105.5M)
Accounts Payable	1.3M	874.0K	868.3K	1.7M	2.0M	1.3M
Cash	8.1M	9.1M	9.8M	4.7M	4.3M	6.6M
Cash And Short Term Investments	8.1M	9.1M	9.8M	4.7M	4.3M	6.6M
Common Stock Shares Outstanding	177.0K	223.5K	262.0K	278.6K	320.4K	304.4K
Liabilities And Stockholders Equity	9.4M	10.6M	11.9M	7.1M	8.1M	10.1M
Non Current Liabilities Total	5.1M	5.6M	6.1M	6.6M	6.0M	4.8M
Other Current Assets	952.1K	935.3K	964.5K	932.6K	1.1M	570.4K
Other Stockholder Equity	95.7M	111.0M	119.7M	120.9M	139.0M	75.9M
Total Liab	12.6M	7.0M	7.8M	9.6M	8.7M	6.5M
Total Current Assets	9.3M	10.6M	11.7M	6.8M	7.9M	10.0M
Common Stock	2.4K	2.7K	3.3K	334.0	384.1	364.89
Short Long Term Debt Total	5.2M	5.0M	5.1M	5M	5.8M	4.1M
Net Tangible Assets	4.4M	(3.2M)	3.6M	4.1M	3.7M	4.2M
Non Current Assets Total	153.3K	12.4K	129.1K	241.6K	217.5K	228.3K
Short Term Debt	245.9K	24.9K	258.1K	5M	5.8M	6.0M
Net Invested Capital	1.9M	8.6M	9.1M	2.4M	2.8M	5.1M
Net Working Capital	1.7M	9.2M	10.1M	3.8M	4.4M	6.1M
Capital Stock	2.4K	2.7K	3.3K	334.0	300.6	285.57

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Evoke Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Evoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Evoke Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Evoke Pharma Stock:

How To Invest In Evoke

Details

Is Evoke Stock a good investment?

Details

What is Evoke Pharma's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evoke Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.

You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(10.06)

Revenue Per Share

7.792

Quarterly Revenue Growth

0.698

Return On Assets

(0.34)

Return On Equity

(3.50)

The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Evoke Free Cash Flow Per Share vs Days Payables Outstanding Analysis

Free Cash Flow Per Share vs Days Payables Outstanding

Free Cash Flow Per Share vs Days Payables Outstanding Correlation Analysis

Correlation Coefficient

Free Cash Flow Per Share

Days Payables Outstanding

Evoke Pharma fundamental ratios Correlations

Evoke Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Evoke Pharma fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Cash	+ 0.98	Total Assets
Cash And Short Term Investments	+ 0.98	Total Assets
Retained Earnings Total Equity	+ 0.98	Retained Earnings
Total Current Assets	+ 0.98	Cash

Common Stock Total Equity	- 0.97	Retained Earnings
Retained Earnings Total Equity	- 0.96	Common Stock Total Equity
Long Term Debt Total	- 0.95	Net Tangible Assets
Other Stockholder Equity	- 0.94	Retained Earnings
Retained Earnings Total Equity	- 0.92	Other Stockholder Equity
Long Term Debt Total	- 0.91	Other Assets